HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report

HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report

HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–re...

Full description

Bibliographic Details
Main Authors: Aiko Ogimoto, MD, Naoko Katsurada, MD, PhD, Atsuhiko Yatani, MD, Chihiro Mimura, MD, Masatsugu Yamamoto, MD, PhD, Motoko Tachihara, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:JTO Clinical and Research Reports
Subjects:
HIP1-ALK
BRAF V600E
Lung adenocarcinoma
Resistance mechanism
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001558
Description
Summary:HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs.
ISSN:2666-3643

Similar Items